TP53 and metastatic prostate carcinoma: As BRCA2 mutation is enriched in metastatic prostate cancer, TP53 mutation or RB1 deletions are also enriched in metastatic disease, whereas SPOP mutation is more frequent in localized disease [6,21,22,28,29].